Pharmafile Logo

Covidien

Teva launches online cancer portal My Day

Follows social listening project on gender differences in cancer discussions

EU flag

Italian pharma scandals prompts call for EU-wide pricing probe

Aspen fined €5.2m for threat to halt supply of cancer drugs if price hikes not accepted

Novartis building

Anxiety over CAR-T follows Novartis closure of cell therapy unit

Firm maintains lead ALL project still on course for 2017 filings despite restructuring

A stumble, but not a fall – what’s next for Opdivo?

Blue Latitude Health's Louis Perdios talks about the daunting challenges faced by BMS after Opdivo's disappointing results.

Blue Latitude Health

Immuno-oncology; bringing patients closer to treatment

What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment?

Blue Latitude Health

- PMLiVE

Ireland’s Mallinckrodt buys US regenerative medicine firm

Stratatech’s StrataGraft in phase III testing for burns treatment

- PMLiVE

NICE swayed by extra data on Amgen’s Imlygic

Cost effectiveness watchdog backs immunotherapy in final draft guidance

Immunotherapy in oncology

Consultant David Cooney explores the medical insights, unmet needs, and future of the vastly growing area of immunotherapy as the fourth pillar in oncology.

Blue Latitude Health

- PMLiVE

Amgen enters into $540m immunotherapy collaboration

Acquires global rights to Advaxis’ preclinical oncology candidate ADXS-NEO

- PMLiVE

Immunotherapy and future directions in oncology

How the field of cancer drugs is expanding as technology improves

Wearables’ impact on cancer patients’ quality of life to be tested

Project sees the Memorial Sloan Kettering Cancer Center collaborate with Medidata

- PMLiVE

Juno cleared to restart CAR-T trial after deaths

Study attributes fatalities to pre-conditioning therapy, not the cancer immunotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links